Telix Pharmaceuti…
USUSDTelix Pharmaceuticals Limited (US:TLPPF) — Biotechnology: Pharmaceutical Preparations. Antal børser, hvor selskabets aktier handles: 1. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.
Om virksomheden
- Websted
- telixpharma.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hovedkontor
- NORTH MELBOURNE, Australia
- Administrerende direktør
- Mr. Raphael Ortiz L.L.B., M.B.A.
- Ansatte
- 1 120
- Udestående aktier
- 338.78 mio. pr. 2025-12-31
- Free float
- 273.61 mio.
- Markedsværdi
- 3.82 mia. USD
- Insidere
- 15.83%
- Institutionelle investorer
- 34.22%
- Branche (SIC)
- Pharmaceutical Preparations
Beskrivelse
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Børser og tickere
| Børs | Ticker | Valuta | Pris | Type |
|---|---|---|---|---|
| US USA Stocks | TLPPF | USD | 10.95 +1.39% | almindelige aktier |
Udbytte
Ingen udbyttebetalinger fundet (tjekket 07.10.2026). Virksomheden udbetaler sandsynligvis ikke udbytte.
Nyheder denne uge
Endnu ingen nyheder fra virksomhedens websted.
Største ejere
| Ejer | Andel | Aktier | Rapportdato |
|---|---|---|---|
| Behrenbruch (Christian P… | ≈6.31% | 21.4 mio. | 2026-04-29 |
| VANGUARD STAR FUNDS-Vang… | 1.21% | 4.1 mio. | 2026-07-31 |
| VANGUARD TAX-MANAGED FUN… | 0.81% | 2.74 mio. | 2026-06-30 |
| DFA INVESTMENT TRUST CO-… | 0.33% | 1.13 mio. | 2026-07-31 |
| VANGUARD Intl Eqy. INDEX… | 0.19% | 652 331 | 2026-07-31 |
| SCHWAB STRATEGIC TRUST-S… | 0.18% | 613 527 | 2026-05-31 |
| Fidelity Rutland Square… | 0.1% | 339 965 | 2026-07-31 |
| VANGUARD Intl Eqy. INDEX… | 0.09% | 298 322 | 2026-07-31 |
| VANGUARD Intl Eqy. INDEX… | 0.07% | 233 321 | 2026-07-31 |
| College Retirement Equit… | 0.06% | 202 548 | 2026-06-30 |
| Fidelity Salem Street Tr… | 0.05% | 156 851 | 2026-07-31 |
| Olson (Tiffany) (Indepen… | ≈0.03% | 106 550 | 2025-03-05 |
| McDonald (Marie Elizabet… | ≈0% | 3 719 | 2025-03-05 |
| Kluge (Andreas) (Former) | — | 0 | 2024-10-17 |
| McCann (Harry Kevin) (Fo… | — | 0 | 2025-05-21 |
